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CD34 § cells in human cord blood and marrow are known to give rise to dendritic cells (DC),
as well as to other myeloid lineages. CD34 § cells are rare in adult blood, however, making it
difficult to use CD34 + ceils to ascertain if DC progenitors are present in the circulation and
if blood can be a starting point to obtain large numbers of these immunostimulatory antigenpresenting cells for clinical studies. A systematic search for DC progenitors was therefore carried
out in several contexts. In each case, we looked initially for the distinctive proliferating aggregates
that were described previously in mice. In cord blood, it was only necessary to deplete erythroid
progenitors, and add granulocyte/macrophage colony-stimulating factor (GM-CSF) together with
tumor necrosis factor (TNF), to observe many aggregates and the production of typical DC
progeny. In adult blood from patients receiving CSFs after chemotherapy for malignancy, GMCSF and TNF likewise generated characteristic DCs from HLA-DR negative precursors. However,
in adult blood from healthy donors, the above approaches only generated small DC aggregates
which then seemed to become monocytes. When interleukin 4 was used to suppress monocyte
development (Jansen, J. H., G.-J. H. M. Wientjens, W. E. Fibbe, K. Willemze, and H. C.
Kluin-Nelemans. 1989. J. Exp. Med. 170:577.), the addition of GM-CSF led to the formation
of large proliferating DC aggregates and within 5-7 d, many nonproliferating progeny, about
3-8 million cells per 40 ml of blood. The progeny had a characteristic morphology and surface
composition (e.g., abundant HLA-DK and accessory molecules for cell-mediated immunity) and
were potent stimulators of quiescent T cells. Therefore, large numbers of DCs can be mobilized
by specific cytokines from progenitors in the blood stream. These relatively large numbers of
DC progeny should facilitate future studies of their FceRI and CD4 receptors, and their use
in stimulating T cell-mediated resistance to viruses and tumors.

endritic cells (DC) 2 provide an effective pathway for

presenting antigens to T cells in situ, both self-antigens
D
during T cell development and foreign antigens during im-

munity (for a review see reference 1). As such, the delineation of developmental pathways for DCs themselves is of some
importance. By identifying the sites in which DC progen-

1 S. Gruner was a visiting scientist from the Charit6, HumboldtUniversity,Berlin, Germany.He diedin a tragic avalancheaccidentin April
1993.

2Abbreviation used in thispaper: DC, dendritic cell.
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itors are found, as well as the requisite cytokines for their
proliferation and maturation, one would have much better
access to a cell type that mediates clonal deletion of autoreactive T cells in the thymus (2) as well as clonal sensitization
of peripheral T cells (3-6).
Two features are well described for the DC developmental
pathway: DCs can originate from bone marrow progenitors
(7-10), and both the proliferation and maturation of DCs
are enhanced by the cytokine GM-CSF (11-21). Early detailed
descriptions of the formation of DCs from proliferating progenitors were obtained using mouse blood (11) and shortly
thereafter, mouse marrow (12). It was noted that an M H C
class II negative precursor could be driven to form distinctive, proliferating aggregates which in turn gave rise to typ-
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Summary

Materials and Methods
Culture Medium. We used RPMI 1640 supplemented with 200
mM L-glutamine, 50 #M 2-ME, 20/~g/ml gentamicin, and either
5-10% FCS (56~ for 0.5 h; Seromed-Biochrom KG, Berlin, Germany) or, in some experiments with 5% cord blood serum.
Recombinant Human Cytokines. GM-CSF (3.1 x 106 U/rag)
was kindly provided by Dr. E. Liehl (Sandoz Research Institute,
Vienna, Austria); TNF-c~ (6 x 107 U/rag) by Dr. G. R. Adolf
(Ernst Boehringer Institut flit Arzneimittelforschung, Vienna, Austria); and IDlc~ (3 x 10s U [D10 assay]/mg) by Dr. P. Lomedico
(Hoffmann La Roche Inc., Nutley, NJ). Ib4 was commercially obtained material (107 U/mg) (Genzyme Corp., Cambridge, MA) or
supernatant from IL-4 gene-transfected COS cells (3 x 104
U/ml), kindly provided by Dr. G. Le Gros (Ciba-Geigy Ltd., Basel,
Switzerland). M-CSF (1.9 x 106 U/mg) was a gift of Dr. S. Clark
(Genetics Institute, Cambridge, MA). IL-3 and G-CSF were purchased from Genzyme Corp.
mAbs. We used the following mouse mAbs (see reference 24
uuless defined here): W6/32, anti-HLA-A,B,C (HB95 from the
American Type Culture Collection, [ATCC] Rockville, MD); L243,
anti-HLA-DR (Becton Dickinson & Co. [BD], Mountain View,
84

CA); 9.3F10, anti-HLA-DR+DQ (HB180 from ATCC); RFD1,
anti-HLA-DQ-related (gift of L. W. Poulter, Royal Free Hospital,
London, England); B7/21, anti-HLA-DP (BD); UCHbl, antiCD45RO (Dako Corp., Glostmp, Denmark); 4G10, anti-CD45RA;
3C10 and LeuM3 (BD), anti-CD14; EBM11, anti-CD68 (Dako);
LeuM1, anti-CD15 (BD); LeuM9, anti-CD33 (BD); HPCA-1, antiCD34 (BD); Leullb, anti-CD16 (BD); 2A3, anti-CD25 (BD); IV.3
(M. Fanger, Dartmouth College Medical School, Hanover, NH)
and CIKM5 (G. Pilkington, MacCallum Hospital, Melbourne, Australia), anti-FcyRII/CD32; 15-1, anti-FceRI (J.-P. Kinet, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, RockviUe, MD [25]); OKT-6, anti-CDla (Ortho Pharmaceuticals, Raritan, NJ); Leu4 (BD) and OKT-3 (Ortho), antiCD3; Leu3a+b, anti-CD4 (BD); Leul, anti-CD5 (BD); Leu2a,
anti-CD8 (BD); Leu12, anti-CD19 (BE)); Leu16, anti-CD20 (BD);
VIB-E3, anti-CD24 (W. Knapp, University of Vienna, Vienna,
Austria); G28-5, anti-CD40 (J. A. Ledbetter, Bristol-Myers Squibb
Pharmaceutical Research Institute, Seattle, WA); TB133, anti-leukocyte function-associated antigen 1 (LFA-1)/CD11a and CLB54,
anti-CD18 (both from S. T. Pals, Free University, Amsterdam, The
Netherlands); LeuMS, anti-CD11c (BD); 7F7, anti-intercellular
adhesion molecule 1 (ICAM-1)/CD54 (M. P. Dierich, University
of Innsbruck, Innsbruck, Austria); AICD58, anti-LFA-3/CD58
(Immunotech, Marseille, France); BB1, anti-B7/BB1/CD80 (E. A.
Clark, University of Washington, Seattle, WA); Lag, anti-Birbeckgranule-associated (M. Kashihara-Sawami, Kyoto University, Kyoto,
Japan [26]); VIE-G4, antiglycophorin (O. Majdic, University of
Vienna); and Ki-67, proliferation-associated antigen (Dako [27]).
Culture of DC from Cord Blood. Cord blood was collected according to institutional guidelines during normal full-term deliveries. PBMC were isolated by flotation on Lymphoprep (Nycomed,
Oslo, Norway), washed, incubated once in saturating concentrations of antiglycophorin mAb anti-HLA-DK and anti-CD3,
washed, panned (10 min on ice, then 20 min at room temperature)
twice onto bacterial petri dishes coated with goat anti-mouse Ig
(H+L) Ab (Jackson ImmunoResearch Laboratories, West Grove,
PA). The nonadherent fractions were then plated in 24-weUdishes
(Costar Corp., Cambridge, MA) and cultured as described in detail in Results.
Culture of DCs from the Bloodof CancerPatients. Peripheralblood
was obtained with the informed consent of cancer patients in complete remission during hematopoietic recovery after high-dose consolidation chemotherapy and subcutaneous daily administration of
G-CSF (300 gg human rG-CSF [Neupogen; Hoffmann-LaRoche,
Basel, Switzerland] to 15 patients with leukemias/lymphomas, and
to two patients with solid tumors, or GM-CSF (400 gg human
rGM-CSF [Leukomax; Sandoz, Basel, Switzerland] to one patient
with leukemia and two patients with solid tumors. PBMC were
prepared by sedimentation in Lymphoprep, coated with anti-HLADR plus anti-CD3 mAbs, washed, and panned twice as described
above. Nonadherent, depleted fractions were then processed according to the protocol described in detail in Results.
Culture of DC from the Blood of Healthy Adults. PBMC were
obtained from either 40-100 ml heparinized fresh whole blood or
leukocyte-enriched buffy coats (28), and processed as described in
detail in Results.
PhenotypicAnalysis. We per formed phenotypic analysisexactly
as described previously (29) by immunolabeling and flow cytometry analysis, and by immunoperoxidase/immunofluorescence on
cells cytospun or attached by poly-t-lysine to glass slides.
T Cell Stimulation Assays. Allogeneic primary MLR and oxidative mitogenesis were performed exactly as described (29).

ProliferatingDendritic Cell Progenitors in Human Blood

Downloaded from http://rupress.org/jem/article-pdf/180/1/83/498078/83.pdf by Rockefeller University user on 29 July 2020

ical nonproliferating DC progeny. The latter exhibit a tetrad
of features: irregular cell shape and motility, abundance of
surface molecules that are involved in effective antigen presentation, potent stimulation of quiescent T cells in the MLIL
(11, 12) and mycobacterial response (22), and homing to the
T cell areas of lymphoid tissues in situ.
Prior reports have also defined DC precursors in humans,
primarily within the CD34 + progenitor pool in cord blood
(14, 15) and adult marrow (16, 23). However, the applicability of this information has been somewhat limited by the
need to start with the trace CD34 § subset. To date, the
reported yields of progeny also are small if one is aspiring
to use DCs to manipulate the immune response in autologous human T cells. Given the capacity of DCs to elicit strong
antigen-specific helper and killer T cell responses (1), one would
like to identify accessible sites containing human DC progenitors as well as pathways for their proliferative expansion.
Since blood is the most accessible tissue for clinical studies,
we set out to extend the findings that were reported in mouse
blood to humans. However, when we tried to induce DC
growth by adding GM-CSF to human blood, we identified
actively proliferating DC aggregates only infrequently. Rather
than conclude that DC progenitors were present in mouse
blood but absent from human blood, we performed a stepwise analysis of the criteria and progenitor populations that
exist in human blood in different situations. As is described
here, the parameters that were productive with mouse blood
(11) were indeed applicable to humans as long as one began
with neonatal cord blood from adults who were receiving
CSF replacement after chemotherapy. Knowing that the
criteria could be extended from mice to humans, we then
returned to normal blood from healthy adults. Conditions
for the generation of large numbers of typical DCs from aggregates of proliferating progenitors were identified. A combination of GM-CSF and IL-4 reproducibly provides about
3-8 million potent DCs from a 40-ml blood sample.

The subsequent events were similar to those described previously with mouse blood. First, small adherent aggregates
appeared after 4-7 d (Fig. 1, A and B). Many of the peripheral cells displayed a veiled or dendritic appearance, and these
adhered loosely to a nest of spindle-shaped cells. Nonadherent
cells could be removed by careful rinsing in warm medium,
but this was not essential. The adherent aggregates enlarged
over the next 7-10 d, indicating proliferative activity (Fig.
1 C). Typical "veiled" DCs (Fig. 1, D and E) were then
released. These DC aggregates only developed if GM-CSF
was added to the medium. TNF although not essential, increased aggregate size and DC yield by 50-100%. It was advantageous to remove the TNF during the last 1-2 d of culture to permit the release of single, mature DCs.
The released DCs were identified by three sets of criteria.
First, the cells by inverted phase contrast microscopy showed
characteristic thin motile cytoplasmic processes or veils (Fig.
1, D and E). The typical ultrastructure of DCs was noted
by electron microscopy (see below). Only one Langerhans cell granule (Birbeck granule) was found in 100 cell
profiles. Second, the DCs had the standard phenotype i.e.,
HLA-DR rich but negative for markers of other cells, e.g.,
CD3/14/19/20. Like epidermal Langerhans cells, CDla was
detected but only 1-2% of the cells reacted with an antigen
associated with Langerhans cell granules (anti-Lag) (26). It

Figure 1. Development of DCs in liquid cultures of cord blood mononudear cells supplemented with GM-CSF and TNF. After 6 d, small adherent
aggregates are visible under the inverted phase contrast microscope (A). Higher magnification reveals that they display typical veils at their edges (white
arrows), and are af~xed to adherent spindle-shaped cells (B). At day 14, the DC aggregates have become much larger (C), and then finally release typical
single DCs which display many processes (D, bright field), notably characteristic veils (arrow indicates one such veil that appears en face) (E, phase
contrast). (A and C) x25; (B) xl00; (D and E) x350.
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Results
We systematically evaluated three different situations to
generate DCs from proliferating progenitors in blood. Our
goals were to define requisite criteria and cytokines for proliferating DCs, but at the same time to avoid the need to enrich
for CD34 + progenitor populations which are so few in
number.
Cord Blood Mononuclear Cells as a Source for DC Progenitors. We began with cord blood, since a prior report had
shown that 0.5-106 enriched (>95%) CD34 + cord blood
cells could give rise to 1-2.5 x 107 DCs if cultured for 14
d in a combination of GM-CSF and TNF (14). A limitation
to this previous protocol was that cord blood only contains
0.9-2.6% CD34 § cells (30). Therefore, we assessed a prior
technique with adult mouse blood (11) in which unfractiohated cells or MHC class II negative cells, were cultured in
GM-CSF. We found that the varying, yet substantial percentage of nucleated erythroid cells in human cord blood was
toxic and that these could be removed by panning with antiglycophorin A mAb. We began, then with erythroiddepleted cord blood cells with a low buoyant density (<~1.077
g/ml) and plated these at 1-2 x 106/ml in 1 ml of standard
medium supplemented with GM-CSF (400-800 U/ml) +
TNF (50 U/ml). The wells were fed every other day by
aspirating 0.3 ml medium and adding back 0.5 ml medium
with cytokines.

""

CORD

BLOOD

~,,ooooi

BLOOD

NORMAL
BLOOD
. ?C(GM+TNF)
'~176176176
1
X

AI "~176176176
.,oc(~+~,,B( .oooI

~ ,ooooo1
.=

PATIENT

~-., DC(GM+TNF)/ '~176176176176
t
~ +ILl

,oooo

"~176176176

.oooo \\
,oooo
\\
0
oJ ~
30;00

,o'oo

- " %

/ ,ooooo,o,
/.oooo
t
\
/
o" none _~_ ,~0

,'o

,o~00

.~o

"

,;o

I

f

N.

r,,

"

,o

,..~O,o0000N-I
OR M A L B L O OD!%1 , o 0NoO0R[ JM~A- "L- - ~ ~B~ L O O D
800001

-

i.oooo

~

\\

...oooo

30000

$000

I

:z:

300

30

30000

-

s~o

:

.oooo

j.ooo:

,,

,o'oo

,000o0N
L O _R M~ A \ B L O __

..,

I

o so;oo

o
.ooo
.ooo

3000

300

SO

30000

3000

300

30

Number of stimulator c e l l s / well

Figure 2. T cell stimulatory function (primary allogeneic MLR) of dendritic cells (DC) grown from cord blood with GM-CSF plus TNF-ot (A),
DC grown with GM-CSF plus TNF from the blood of cancer patients after high-dose chemotherapy and G-CSF treatment (/3), and DC grown from
normal peripheral blood with GM-CSF plus TNF-ot (C), or with GM-CSF plus II.,4 (D-F). Responder cells were purified T lymphocytes (2 x 105
in 96 flat bottom wells). Equal numbers of irradiated (3,000 rad, 137Cs)blood DC (0, all panels) as identified by FACS| analyses (CDla §
+
cells, compare with Fig. 5) were compared both with cultured epidermal Langerhans cells (LC) from the same donor in D and with poorly stimulating
cell populations (whole PBMC in D and E; adherent macrophages from the same cultures in C; and control cultures grown in the absence of cytokines
in F [A]). Note that DC are 10-50-fold stronger than PBMC (D and E) or macrophages (C) and that they are comparable with DC from skin (D).
In addition, B and E show the enhancing effect of II.-1 (added during the last 24 h of culture) on the T cell stimulatory capacity of DCs. Without
cytokines, no immunostimulatory DCs develop in the cultures (F).

is interesting to note that these were in the center of rare
residual aggregates. Third, the cord blood-derived DCs were
potent stimulators of resting T cells in the primary MLR
(Fig. 2 A) as well as oxidative mitogenesis (data not shown).
The inclusion of TNF in the culture medium increased the
immunostimulatory function of the DCs (Fig. 2 A).
T a b l e 1.

The above protocol has proven reproducible in 21 standardized experiments and generates 1-5 x 106 DCs from
40 ml of cord blood at a purity of 20-50% (Table 1). Purity
can be increased to >80% by flotation on metrizamide (28)
columns. We conclude that (a) it is not necessary to enrich
for CD34 + precursors to generate typical DCs from cord

DC Progenitors in Human Blood
Enrichment of D C
progenitors

Type of blood donor

Time of
culture

D C yields/
40 ml blood

Percent D C
enrichment

d
10-20

1-5 • 106

%
20-50

Cytokines
added

Neonatal, cord blood

Remove glycophorin +
erythroid cells

Adult blood, patients,
chemotherapy, and
CSF therapy

Remove CD3 § and
H L A - D R + cells

16

4-8 x 106

60-80

GM-CSF
TNF-cr

Adult blood, normal

Bulk PBMC,
adherent and
loosely adherent

5-7

3-8 • 106

40-80

GM-CSF
IL-4
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blood, and (b) the criteria that proved useful in identifying
aggregates of proliferating progenitors in mouse blood are
also applicable to human cells.

DC Progenitorsin the Blood of Cancer Patientsduring HematopoieticRecoveryfrom Chemotherapy. We next studied blood

Figure 3. Development of DCs in liquid cultures of normal, adult blood mononuclear cells supplemented with GM-CSF plus Ib4. On day 2.5,
small adherent DC aggregates are readily visible under the inverted phase contrast microscope (tt). On day 7, the DC aggregates have become nonadherent, very large, and loose (B). The nonadherent fraction of the cultures was harvested and vigorously resuspended to obtain single DCs in large
numbers (C, arrows mark some veils). (A and B) x25; (C) xS00.
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mononuclear cells from cancer patients in full remission
(leukemias/lymphomas and solid tumors) after high-dose chemotherapy and either G-CSF (17 patients) or GM-CSF (3
patients) treatment. It is known that in the hematopoietic
recovery of such patients, progenitors are mobilized into the
blood in substantial numbers (0.5-6.0% CD34 + cells) (31,
32). Instead of enriching for CD34 + cells, we simply removed CD3 + and D R + cells by panning, and then plated
1-2 x 106 cells in 1 ml of medium with 5-10% FCS or 5%
cord serum plus 400-800 U/ml GM-CSF. The nonadherent
cells were transferred at day 2 (or in some experiments at
day 1) and cultured for 16-d feeding every other day.
Growing DC aggregates appeared on day 3-5 and expanded
in size until day 11 (data not shown, but compare with Fig.
3). The aggregates developed peripheral veils and initially were
loosely attached to a stroma but later were nonadherent. The
wells were subcultured, e.g., one well split to two to three
wells, when the cell density increased, or if more tightly adherent, smooth, non-DC clusters appeared (contaminating
macrophage and granulocyte progenitors). When the DC aggregates became very large (day 12-16), it was easy to dissociate the cells and float the mature DCs on metrizamide
columns.
The DCs that developed in this manner had a typical mot-

phology by light and electron microscopy (data not shown,
but comparable to Figs. 3 and 6). The phenotype was again
MHC class II rich but null for CD3/14/19/20 (data not
shown). MLR stimulatory function was potent (Fig. 2 B).
In contrast to cord blood-derived DCs, CDla and Lag antigens were not seen (data not shown).
GM-CSF proved essential for DC development. G-CSF,
M-CSF, and IL-3 were inactive. Exposure to 3,000 tad of
ionizing irradiation blocked DC development. Addition of
TNF at 10-50 U/ml usually, though not always, increased
DC yields up to twofold, and always improved the function
of DCs (Fig. 2 B). Human rlL-1 (50 LAF U/ml), when added
during the last 24 h in some experiments, further increased
function (Fig. 2 B).
Starting from 40 ml blood, and using both GM-CSF and
TNF, the yield (Table 1) of mature DCs was 4-8 x 106 at
16 d with 60-80% purity. This is at least 20 times the yield
of mature DCs in fresh normal blood (28, 33).
ProliferatingDC Aggregatesfrom NormalAdult Blood. When
we applied the above methods to blood from healthy adults,
we did observe some small, adherent, veiled aggregates between days 8 and 16. In all 20 experiments, the aggregates
then deteriorated and did not enlarge, leaving behind nonviable cells or less often, a few macrophages. Because a stromal
monolayer was not evident in the cultures, we next omitted
the panning step with anti-CD3 and HLA-DR in case the
panning antibodies removed required accessory cells. We
simply plated 106 bulk mononuclear cells in 1 ml of medium
with GM-CSF (800 U/ml) and TNF (50 U/ml), and after

88

Figure 4. Phenotype and proliferation characteristics of DCs grown
from normal blood with GM-CSF plus 1I.-4. Fluorescence pictures in each
row represent identical microscopic fields of double-labeled cytospin preparations. (Left) Panels are stained with anti-HLA-DR. DCs grown in GMCSF and 11.-4 are strongly HLA-DR positive (A, left) but display only
a dull spot of anti-CD68 reactivity (right). In contrast, control cells grown
in parallel without cytokines (mainly macrophages) show an inverted pattern: very low HLA-DR (B, left) but brilliant CD68 expression (right).
mAb Lag (C, right) identifies occasional Birbeck granule containing cells
in the center of an HLA-DIL-expressing aggregate of DC (left). Peroxidase staining of nuclei and nucleoli with mAb Ki-67 (D) demonstrates
that proliferation occurs predominantly in aggregates (/eft); singly dispersed
DC derived from firmly adherent cells (see text) are not stained (rigkt).

(A-C) • 200; (D) • 100.

At that time, growth essentially ceased. The aggregates then
could be disassembled by pipetting into DCs with a typical
surface phenotype (Fig. 5), characteristic morphology at the
light (Fig. 3 C) and electron microscopy levels (see Fig. 6),
and strong T cell stimulatory function (Fig. 2, D-F). Human
rlL-1 (50 LAF U/ml), when added during the last 24 h of
culture, amplified the stimulator), function of DCs as ob-
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1 d, gently removed the nonadherent lymphocytes. We then
observed the adherent cells every 12 h under the inverted microscope. To our surprise, many small adherent aggregates
developed within 2 d, and most were covered with typical
DC veils. However within two more days, the aggregated
cells became round and gave rise to a monolayer of macrophages. These events took place whether GM-CSF or GMCSF plus TNF were added. However, by day 12-16, typical
expanding DC aggregates appearedin some of the wells. These
aggregates were loosely affixed to an adherent monolayer as
previously observed in mouse blood (11) (data not shown).
The DCs that were released were typical in morphology,
phenotype (data not shown), and T cell stimulatory function (Fig. 2 C). The yield was about 4% of the initial number
of mononuclear cells plated, which is far greater than the
0.5-1% yield of DCs in fresh blood (28, 33).
We suspected from these findings that DC precursors were
actually quite numerous in blood, but that the precursor still
had the potential to give rise to macrophages. The latter is
known to be the case for the CFUs that GM-CSF induces
in mouse (34). Since IL-4 at 500-1,000 U/ml blocks macrophage colony formation (35), we added IL-4 to GM-CSF and
repeated the experiments.
The combination of GM-CSF and IL-4 produced two
striking findings. First, the numerous, initial veiled aggregates
(Fig. 3 A) did not transform into macrophages but rather
increased rapidly in size over the next few days (Fig. 3 B).
The aggregates became nonadherent, displayed typical veils
all over the periphery, and began to release mature DCs (Fig.
3 C). Second, the single adherent cells (presumably monocytes) that were scattered in between the small adherent aggregates, also became nonadherent and developed processes
similar to those of typical DCs (data not shown). Growing
DC aggregates only formed in the presence of both GMCSF and IL-4. The initial nonadherent fraction also developed some aggregates but these were obscured by the excess
of lymphocytes.
After having made these observations in 20 experiments,
we found it simpler to use larger 35-mm wells. The protocol
was to plate 5-20 x 106 plain bulk mononuclear cells in 3
ml of medium, to discard the nonadherent cells at 2 h with
a very gentle rinse, and to then culture the adherent cells
in medium supplemented with GM-CSF (800 U/ml) and IL-4
(500 U/ml). With the above gentle wash, the nonadherent
cells did not develop DC aggregates, but with more vigorous
washing, the aggregates mainly developed in the nonadherent
fraction.
The presumptive DC aggregates were verifiedto be proliferating by two criteria: staining of '~10% of the cells with
the Ki-67 mAb that identifies an antigen in cycling cells (27)
(Fig. 4 D), and sensitivity to 3,000 rad. In contrast, the tightly
adherent populations, which could develop single cells with
the appearance of DCs (see above), were nonproliferating as
evidenced by a lack of staining with anti-Ki-67 mAb (Fig.
4 D) and a resistance to 3,000 rad of irradiation.
The combination of GM-CSF and IL-4 reproducibly gives
rise to large growing DC aggregates over a 5-7-d period.

served with murine DCs isolated from spleen or epidermis
(18, 36). It is interesting to note that the blood-derived DCs
expressed CDla, CD4, and FcdLI as is typical of epidermal
Langerhans cells (25, 37, 38). Birbeck granules were not detectable by electron microscopy, however, and only a rare cell
in the center of a residual D C aggregate stained with antiLag mAb (26) (Fig. 4 C). Anti-CD68 immunostaining revealed a perinuclear zone of reactivity in some of the DCs
(Fig. 4 A), a feature that differs from the strong diffuse granular
staining of macrophages (Fig. 4 B).
The yield of mature, immunostimulatory DCs (Table 1)
was 6-15% of the mononuclear cells plated. This is many
times greater than the number of DCs that can be identified
in unstimulated blood (0.3-1%) (28, 33). The above protocol and yield (3-8 x 106 DCs/40 ml of blood) has proven
89
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reproducible in over 25 experiments with blood from healthy
males and females (25-60-yr-old), using either fresh venipuncture or burly coat preparations.

Discussion

D C Progenitors in Human Blood: Identification. These findings of necessity appear methodological in nature but in fact
outline a pathway whereby the distinct D C lineage can be
induced to proliferate and mature from precursors that are
relatively plentiful in human blood. The methodological caste
of our results reflects the difficulty inherent in identifying
precursors and progeny in this distinctive immunostimulatory pathway. DCs are not yet known to express a lineagespecific surface antigen, as is the case with lymphocytes, e.g.,
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Figure 5. Cytofluorographic analysisof dendritic cells (DC) grown from normal peripheralblood with GM-CSF plus ID4. Two different representative experimentsare shown. EpidermalLangerhanscells (LC)cultured for 3 d were includedin one experimentfor comparison.Three-colorimmunolabeling
was performed. Cells were stainedwith differentmouse mAbs followedin sequenceby biotinylatedanti-mouse Ig, streptavidin-PE,mouse Ig for blocking
free binding sites, and FITC-conjugated anti-HLA-DR. Dead cells and lymphocytes were excluded from analysis by propidium iodide staining and
light scatter properties, respectively.More than 90% of the remaining cells were strongly MHC-dass II positive and constituted DC. The phenotype
of this population is shown (shadedcurves). Isotype-matchedcontrol antibodies are included in each histogram (boldcurves). Blood DC displaya phenotype
typical for DCs as described and almost identical to cultured LC in direct comparison (24, 28, 29, 33). It is notable that they do not express CD14
but have high levels of MHC molecules (HLA-ABC, DR, DQ, and DP), adhesins (CD54, CD58, CDlla [not shown], and CDllc), and costimulatory
molecules (CD40 and B7/CD80). They are also negative with markers for granulocytes (CD15), NK cells (CD16), B cells (CD19 [not shown] and
CD20), and T cells (CD3 and CD8 [not shown]). Expression of CD5 and the staining pattern of CD45RA and -RO are as describedfor DCs isolated
from fresh blood (33).

CD3, CD19, and CD20. A lack of lineage-specific markers
is also typical of the individual human myeloid lineages, e.g.,
monocytes, neutrophils, basophils, and eosinophils. However,
these other myeloid lineages have distinctive tinctorial properties and distinctive CSFs, e.g., M-CSF and G-CSF. DCs,
in contrast, are only known to respond to the multilineage
cytokine GM-CSF (17, 18, 39), and their peculiar morphology,
phenotype, and function is best outlined with a composite
of approaches (1).
Given these inherent difficulties, we searched for criteria
that were similar to those that had been used to identify immature DC progenitors (e.g., MHC class II negative) in mouse
blood (11) and bone marrow (12). Mouse DCs proliferate
within a characteristic aggregate that attaches loosely to an
underlying stroma and is covered with large sheetlike processes
or veils (compare Figs. I and 3). By defining conditions that
give rise to such aggregates, at first containing a few cells
but growing to >10 cells in diameter, we could establish that
90

proliferating DC progenitors are readily detectable in the blood
of all healthy adults, and that one could use these progenitors to generate relatively large numbers of typical immunostimulatory DCs within 7 d, i.e., 3-8 million of such
cells per 40 ml of blood.
The critical finding was that GM-CSF did induce the formation of many small DC progenitor aggregates in human
blood, but that these did not proliferate further and seemed
to become typical macrophages. IL-4, a known inhibitor of
macrophage colony formation (35), allowed extensive DC
growth and maturation to ensue (Fig. 3).
DC Progenitors in Human Blood: Cytokine Requirements. To
study the properties of DC progenitors in blood, it is not
necessary to enrich for CD34 + multilineage progenitors
which are so rare (<0.1%) in normal blood (40). The need
for exogenous cytokines may vary from one experimental situation to another depending on their endogenous production (e.g., TNF) by cells in the culture. However, it is to
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Figure 6. Ultrastructure of DCs grown form normal, adult blood mononuclear cells with GM-CSF plus IL-4. Low power view (x 4,700) shows
three profilesof DCs. (Arrowheads)Veils, i.e., thin cytoplasmicprocessesdevoidof organelles. (Bracket)Area shown at higher magnification (x33,000)
to demonstrate the characteristic abundance of mitochondria and paucity of lysosomes/phagosomes.

CD34 + cells in the CD3/HLA-DR-depleted mononuclear
cell fraction did not strictly correlate with DC yields. In normal
adult blood in response to GM-CSF and TNF-ol and only
after a prolonged culture period (2 wk), some DC aggregates
emerged probably from early, rare DC progenitors similar
to those in cord blood or the blood of cancer patients during
hematopoietic recovery. The main DC progenitor(s) in normal
adult blood, however, appear(s) to be more frequent as only
2 d of culture are needed before many DC aggregates appear
(Fig. 3). Prior work in mice (34) and in humans (16) has
described that the multilineage colonies that are induced by
GM-CSF in semisolid agar cultures contain all three types
of myeloid progeny, i.e., granulocytes, macrophages, and DCs.
The principal DC progenitor in normal human peripheral
blood seems more differentiated since granulocytes do not
develop. This committed progenitor is GM-CSF responsive,
and likely bipotential, developing into macrophages rather
than DCs unless its monocyte differentiation potential is suppressed by IL-4.
DC Progenitors in Human Blood: Clinical Relevance. The
larger numbers of DCs that are now available should help
characterize two other intriguing features of the DC phenotype that are clear-cut in the progeny that can be reared with
GM-CSF and IL-4 from human blood. One is the expression
of FceRI receptors which could have a role in atopic dermatitis (25, 38), e.g., via the presentation of small amounts of
antigen as IgE complexes. A second feature is the high level
of expression of CD4, the principal receptor for HIV-1 (43).
It also may be worthwhile to consider the use of IL-4 and
GM-CSF, perhaps together with antigen-pulsed DC progenitors (22), to enhance immune responses in situ. In any case,
methods for the identification and growth of DC progenitors in human blood, especially normal adult human blood,
should make it feasible to explore the immunogenic potential of these cells in clinical situations, such as the presentation of antigens in resistance to infections and tumors.
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